Clinical Trials
13 trialsNCT05303519 2026-03-05
SIGMA
Nuvation Bio Inc.
Phase 3 Recruiting
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02796261 2022-01-21
STELLAR
Orbus Therapeutics, Inc.
Phase 3 Unknown
NCT00335075 2017-05-15
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00790400 2017-02-17
EXIST-2
Novartis
Phase 3 Completed
NCT00789828 2016-02-03
EXIST-1
Novartis
Phase 3 Completed
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT00088166 2014-08-13
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Celtic Pharma Development Services
Phase 3 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00226655 2012-08-31
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
Celtic Pharma Development Services
Phase 3 Completed
NCT01656980 2012-08-03
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT00154375 2011-04-26
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
Novartis
Phase 3 Completed
NCT00226668 2008-01-03
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
Celtic Pharma Development Services
Phase 3 Withdrawn